Cargando…
The efficacy of IL-6 inhibitor Tocilizumab in reducing severe COVID-19 mortality: a systematic review
BACKGROUND: In the absence of highly effective antiviral therapies against SARS-CoV-2, it is crucial to counter the known pathophysiological causes of severe COVID-19. Evaluating the efficacy existing drugs may expedite the development of such therapeutics. Severe COVID-19 is largely the result of a...
Autores principales: | Kaye, Avi Gurion, Siegel, Robert |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
PeerJ Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7643559/ https://www.ncbi.nlm.nih.gov/pubmed/33194450 http://dx.doi.org/10.7717/peerj.10322 |
Ejemplares similares
-
Construction of an Expression System for Bioactive IL-18 and Generation of
Recombinant Canine Distemper Virus Expressing IL-18
por: LIU, Yuxiu, et al.
Publicado: (2014) -
The utility of MEWS for predicting the mortality in the elderly adults with COVID-19: a retrospective cohort study with comparison to other predictive clinical scores
por: Wang, Lichun, et al.
Publicado: (2020) -
Caspase-3 inhibitor inhibits enterovirus D68 production
por: Huo, Wenbo, et al.
Publicado: (2020) -
Duration of SARS-CoV-2 viremia and its correlation to mortality and inflammatory parameters in patients hospitalized for COVID-19: a cohort study
por: Hagman, Karl, et al.
Publicado: (2022) -
Antibody-dependent enhancement of severe dengue disease in humans
por: Katzelnick, Leah C., et al.
Publicado: (2017)